Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | ANPEP | P15144 | 2/20 | 0.40 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | SCN1A | P35498 | 1/20 | 0.38 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.38 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1246086 | 0.98 | KDM4E (0.54) | KDM4EANPEPERAP2HTTSMN1; SMN2 | |
| SCHEMBL1246156 | 0.98 | KDM4E (0.54) | KDM4EANPEPERAP2HTTSMN1; SMN2 | |
| SCHEMBL2698028 | 0.98 | KDM4E (0.54) | KDM4EANPEPERAP2HTTSMN1; SMN2 | |
| SCHEMBL27036944 | 0.91 | MEN1 (0.42) | KDM4EANPEPERAP2HTTSMN1; SMN2 | |
| SCHEMBL12801234 | 0.83 | MEN1 (0.38) | KDM4EALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL9909550 | 0.78 | KDM4E (0.52) | KDM4EANPEPERAP2HTTSMN1; SMN2 | |
| SCHEMBL3552579 | 0.78 | KDM4E (0.52) | KDM4EANPEPERAP2HTTSMN1; SMN2 | |
| SCHEMBL12800405 | 0.78 | MEN1 (0.33) | KDM4EMEN1KMT2A | |
| SCHEMBL934315 | 0.77 | KDM4E (0.50) | KDM4EANPEPERAP2HTTSMN1; SMN2 | |
| SCHEMBL172662 | 0.75 | KDM4E (0.58) | KDM4EANPEPERAP2HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109195975-B | Diazaspiro [5.5] undecane derivative and application thereof | 四川海思科制药有限公司 | 2022-01-04 | — | — | CN | disclosed |
| CN-107849008-B | Octahydrocyclopenta [ c ] pyrrole derivative, preparation method and medical application thereof | 四川海思科制药有限公司 | 2021-04-09 | — | — | CN | disclosed |
| EP-2459572-B1 | SPIROCYCLIC AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2018-09-12 | — | — | EP | disclosed |
| US-8476265-B2 | Compounds-801 | ASTRAZENECA AB (SE) | 2013-07-02 | — | — | US | disclosed |
| US-8476265-B2 | Compounds-801 | ASTRAZENECA AB (SE) | 2013-07-02 | — | — | US | disclosed |
| US-8476265-B2 | Compounds-801 | ASTRAZENECA AB (SE) | 2013-07-02 | — | — | US | disclosed |
| US-8455483-B2 | Compounds—801 | ASTRAZENECA AB (SE) | 2013-06-04 | — | — | US | disclosed |
| US-8455483-B2 | Compounds—801 | ASTRAZENECA AB (SE) | 2013-06-04 | — | — | US | disclosed |
| US-8455483-B2 | Compounds—801 | ASTRAZENECA AB (SE) | 2013-06-04 | — | — | US | disclosed |
| US-20130018037-A1 | Compounds - 801 | ASTRAZENECA UK LIMITED (GB) | 2013-01-17 | — | — | US | disclosed |
| US-20110053909-A1 | Compounds - 801 | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| US-20110053909-A1 | Compounds - 801 | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| US-20110053909-A1 | Compounds - 801 | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| WO-2011012896-A2 | COMPOUNDS - 801 | ASTRAZENECA AB (SE) | 2011-02-03 | — | — | WO | disclosed |
| WO-2011012896-A2 | COMPOUNDS - 801 | ASTRAZENECA AB (SE) | 2011-02-03 | — | — | WO | disclosed |
| US-20100105642-A1 | NOVEL COMPOUNDS 409 | ASTRAZENECA AB (SE) | 2010-04-29 | — | — | US | disclosed |
| US-20100105642-A1 | NOVEL COMPOUNDS 409 | ASTRAZENECA AB (SE) | 2010-04-29 | — | — | US | disclosed |
| US-20100105642-A1 | NOVEL COMPOUNDS 409 | ASTRAZENECA AB (SE) | 2010-04-29 | — | — | US | disclosed |
| WO-2009154557-A1 | BENZOXAZINONE DERIVATIVES ACTING AS BETA2-ADRENORECEPTOR AGONIST FOR THE TREATMENT OF RESPIRATORY DISORDERS | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009154557-A1 | BENZOXAZINONE DERIVATIVES ACTING AS BETA2-ADRENORECEPTOR AGONIST FOR THE TREATMENT OF RESPIRATORY DISORDERS | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105642-A1 | NOVEL COMPOUNDS 409 | GPR119, CYP4B1, CYP4A11 | KDM4E 779/4885ANPEP 3699/4885ERAP2 3590/4885 |
| US-20130018037-A1 | Compounds - 801 | ADRA2C, ADRB2, ADRB1 | KDM4E 3165/4885ANPEP 2086/4885ERAP2 3128/4885 |
| US-20110053909-A1 | Compounds - 801 | ADRA2C, ADRB2, ADRB1 | KDM4E 3165/4885ANPEP 2086/4885ERAP2 3128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.